swissdamed Registration Now Mandatory: UDI Requirements and Swiss Hospital Tender Eligibility [July 2026]

From 1 July 2026, medical device registration in Switzerland changed fundamentally. Swissmedic's swissdamed UDI Devices database registration is now a legal requirement for all devices placed on the Swiss market — not a voluntary registry, but a mandatory condition of market access. For medical device suppliers bidding on Swiss hospital tenders, the implications are direct: an unregistered device cannot be legally sold in Switzerland and cannot be quoted in a compliant Swiss public procurement bid.

This guide explains what swissdamed registration requires, what the July 1 to December 31, 2026 timeline means for your product portfolio, what UDI data you need to submit, and how registration status affects Swiss hospital tender eligibility.

What is swissdamed?

swissdamed is Switzerland's national medical device database, operated by Swissmedic — the Swiss Federal Institute for Medicinal Products and Medical Devices. It is Switzerland's national equivalent of the EU's EUDAMED (European Database on Medical Devices) and serves a similar function: a centralised, authoritative registry of medical devices authorized for the Swiss market.

The swissdamed database was introduced under the Medical Devices Ordinance (MedDO), Switzerland's primary medical device regulation, which aligns Swiss requirements broadly with EU MDR 2017/745 while maintaining Swiss-specific provisions. Switzerland's approach to device registration mirrors the EU's UDI (Unique Device Identifier) system: manufacturers must assign UDI codes to all devices and register UDI data in the national database before or alongside market placement.

Registration in swissdamed covers three modules. The Economic Operator module registers manufacturers, importers, and other economic operators. The UDI/Device module — which became mandatory from 1 July 2026 — registers individual devices and their UDI data. A vigilance and post-market surveillance module handles incident reporting. This guide focuses on the UDI/Device module, as it is the one directly triggered by the July 2026 deadline and the one that affects tender eligibility.

What changed on 1 July 2026

Before 1 July 2026, swissdamed registration was available as a voluntary system. From that date, MedDO makes registration in the swissdamed UDI Devices module a mandatory requirement for all devices placed on the Swiss market.

The practical implications by device status:

Device status	Registration requirement	Deadline
New devices being placed on market from 1 July 2026	Must be registered in swissdamed before or at point of market placement	Immediate — from 1 July 2026
Devices already on the Swiss market before 1 July 2026	Must complete swissdamed registration during the transition period	31 December 2026
Devices requiring vigilance reporting (serious incidents, FSCAs, trends)	Must be registered immediately — no transition period	Immediate — from 1 July 2026

After 31 December 2026, all devices on the Swiss market — including those placed before July 2026 — must be registered. Continuing to sell or distribute an unregistered device after this date is a regulatory violation under MedDO.

UDI data requirements for swissdamed registration

swissdamed registration requires structured UDI (Unique Device Identifier) data at two levels. Understanding the hierarchy matters because registering at the wrong level or with incomplete data will cause the registration to be rejected:

Basic UDI-DI (device model level)

The Basic UDI-DI identifies the device at the highest level — the device model, product line, or group of configurations that share a common design, intended purpose, and technical documentation. One Basic UDI-DI typically corresponds to one EU MDR Article 10(4) reference in the technical documentation. Required data for the Basic UDI-DI registration:

• Device description and product name
• Risk class (MedDO class I, IIa, IIb, or III — aligned with EU MDR classification)
• Intended purpose and clinical indication
• Special device designations: active implantable, implantable, IVD, custom-made, system or procedure pack
• Single-use designation and reprocessing information
• Sterile state (is the device provided sterile?)
• Issuing agency (GS1, HIBCC, or ICCBBA)
• Manufacturer name and country

Device-specific UDI-DI (individual configuration level)

Each specific device configuration — each size, sterility variant, packaging quantity, or component combination — requires a separate device-specific UDI-DI. This is the identifier printed or applied to the product label. Required data for each device-specific UDI-DI registration:

• UDI-DI code (the specific alphanumeric identifier assigned by the issuing agency)
• Product name and commercial name
• Catalogue or reference number
• Quantity per package (for consumables)
• Size or specification details (for sized devices such as implants)
• Sterility and sterilization method (if applicable)
• Shelf life and storage conditions (for biological or sterile products)
• Link to the parent Basic UDI-DI

If your devices are registered in EUDAMED under EU MDR, you already have this data structured in your UDI submissions. swissdamed uses compatible data fields, meaning your EUDAMED UDI data can be the foundation for your swissdamed registration — though Switzerland requires a separate submission in the Swissmedic system, not a data transfer from EUDAMED. See our EUDAMED registration guide for the EU parallel.

CH-REP obligations: who registers for non-Swiss manufacturers

One of the most critical compliance points for foreign medical device manufacturers is the Swiss Authorised Representative (CH-REP) requirement. Under MedDO, manufacturers established outside Switzerland must appoint a CH-REP before their devices can be placed on the Swiss market. The CH-REP acts as the Swissmedic contact point for all regulatory matters, including:

• Completing swissdamed registration on behalf of the manufacturer
• Maintaining and updating device registration data in swissdamed
• Acting as the vigilance contact for serious incident reports, FSCAs, and trend reports
• Responding to Swissmedic market surveillance enquiries
• Verifying that devices comply with MedDO requirements before placement

EU manufacturers: Since the EU–Switzerland Mutual Recognition Agreement (MRA) on medical devices was not updated to cover EU MDR, EU-established manufacturers who previously relied on the MRA to sell into Switzerland without a CH-REP no longer have that option. All EU manufacturers placing MDR-certified devices on the Swiss market must appoint a CH-REP and complete swissdamed registration. The CE marking under EU MDR is accepted by Swissmedic as evidence of conformity with Swiss requirements, but the administrative obligations (CH-REP, swissdamed registration) apply regardless of CE marking status.

US manufacturers: FDA-cleared (510(k)) or approved (PMA) devices require both EU MDR certification (or MedDO conformity) and Swiss-specific registration. US manufacturers typically work with a CH-REP who also holds EU-authorized representative experience, since the technical documentation requirements overlap significantly.

Swiss hospital tender eligibility and swissdamed registration

The connection between swissdamed registration and hospital tender eligibility is direct: Swiss public procurement law requires that products quoted in public tenders are lawfully marketed in Switzerland. An unregistered device is not lawfully marketed under MedDO after the applicable deadline. This means:

• New tenders after 1 July 2026: Any device model placed on the Swiss market for the first time after July 1 must be registered in swissdamed before it can be included in a Swiss hospital tender bid. Evaluation teams at cantonal hospitals and federal procurement entities are authorized to request registration confirmation as part of bid qualification.
• Tenders completing before 31 December 2026: Devices placed on market before July 2026 benefit from the transition period for swissdamed registration, but the device must still hold valid Swissmedic authorization (valid CH-REP appointment and MedDO conformity) to be tendered. The transition period delays the swissdamed database entry requirement — it does not change the market authorization requirement.
• Framework agreements and multi-year contracts: If your products are included in a Swiss hospital framework agreement or ongoing supply contract, swissdamed registration compliance is required by December 31, 2026 even for products you have been supplying for years. Plan registration completions before contract renewal windows to avoid supply disruption.

Cantonal hospital procurement offices in Switzerland are progressively referencing regulatory compliance databases — including Swissmedic registration status — in tender qualification stages. This mirrors EU hospital procurement practice, where EUDAMED registration and CE marking verification are increasingly included in lot qualification criteria. For your Swiss tender strategy, swissdamed registration should be confirmed before submission for any tender with a contract period extending beyond December 31, 2026.

How swissdamed differs from and relates to EUDAMED

The most common question from EU MDR-registered manufacturers is whether EUDAMED registration satisfies swissdamed obligations. The short answer is no — they are separate systems requiring separate registrations. The longer answer:

Dimension	EUDAMED (EU)	swissdamed (Switzerland)
Operator	European Commission (EUDA)	Swissmedic
Legal basis	EU MDR 2017/745, EU IVDR 2017/746	MedDO (Medizinprodukteverordnung)
Mandatory from	UDI/Device: mandatory May 2026 for most device classes	1 July 2026 (devices placed on market); 31 Dec 2026 transition for existing devices
UDI standard	GS1, HIBCC, or ICCBBA	GS1, HIBCC, or ICCBBA (same agencies)
Data fields	EUDAMED-specific data model	Compatible structure; separate Swiss submission required
Market access gate	EU 30 member states + EEA	Switzerland only
Representative requirement	EU Authorised Representative (EU-REP) for non-EU manufacturers	CH-REP for all non-Swiss manufacturers (including EU)

Practically, if you have completed EUDAMED registration for EU MDR, the swissdamed data submission process is significantly lighter because your UDI data is already structured and verified. You still need to submit separately to swissdamed via Swissmedic's platform, and you still need a CH-REP in place, but the underlying device data (descriptions, UDI codes, risk class, intended purpose) transfers directly from your EUDAMED preparation work.

Compliance checklist for the swissdamed transition

Use this checklist to confirm registration readiness for each device model in your Swiss product portfolio:

Before 1 July 2026 (or at first Swiss market placement for new devices)

• CH-REP appointed and MedDO registration information updated with CH-REP details
• UDI issuing agency assigned (GS1, HIBCC, or ICCBBA) and all device models assigned Basic UDI-DI codes
• Device-specific UDI-DI codes assigned for all individual configurations in your Swiss product portfolio
• swissdamed Economic Operator module registration completed for manufacturer and CH-REP
• UDI/Device module registration submitted for all devices being placed on the Swiss market from July 1

Before 31 December 2026 (transition deadline for existing devices)

• All device models placed on the Swiss market before 1 July 2026 registered in swissdamed UDI/Device module
• Registration verified for all products included in active Swiss hospital framework agreements or supply contracts
• CH-REP authority confirmed to act as swissdamed registrant and vigilance contact
• Swiss hospital tender bids updated to confirm swissdamed registration status where requested
• Internal process established for maintaining swissdamed data accuracy (product descriptions, certificate status, UDI changes)

Ongoing after December 2026

• New device models registered in swissdamed before first Swiss placement
• Changes to registered device data (description, UDI, specifications) updated in swissdamed within Swissmedic-required timeframes
• Serious incident, FSCA, and trend reports submitted via swissdamed vigilance module when required
• Annual confirmation of CH-REP authority and mandate currency

Impact on tender documentation and compliance evidence

Swiss hospital tenders increasingly include compliance qualification sections where suppliers must confirm market authorization status. The specific documents typically requested in Swiss public procurement qualification stages include:

• Swissmedic registration confirmation: A copy of the CH-REP letter or Swissmedic acknowledgement of registration. After the swissdamed mandatory date, a registration confirmation screenshot or extract from swissdamed may also be requested.
• CH-REP appointment letter: The formal appointment document between the manufacturer and the Swiss Authorised Representative, including the CH-REP's contact details for Swissmedic correspondence.
• CE marking certificate or MedDO conformity document: Certificate from the Notified Body (for Class IIa, IIb, and III devices) or the EU Declaration of Conformity (for Class I devices), as accepted by Swissmedic under the current MedDO alignment.
• Swiss labelling compliance confirmation: Confirmation that product labelling and IFU meet the language requirements of the target canton (German, French, Italian, or combinations thereof).

For Swiss hospital tenders, your compliance documentation pack should include swissdamed registration confirmation alongside your CH-REP appointment letter and CE marking documentation from mid-2026 onwards. Procurement teams at major university hospitals (USZ, Inselspital, HUG, CHUV) are sophisticated buyers who will verify regulatory status before shortlisting. Read our Switzerland medical device procurement guide for the complete regulatory and market access context.

How Orbid AI supports Swiss market compliance and tender tracking

Managing swissdamed registration status across a product portfolio — particularly for companies selling in Switzerland alongside EU and other international markets — adds regulatory compliance overhead at every level: CH-REP coordination, UDI data maintenance, certificate validity tracking, and tender qualification documentation preparation.

Orbid AI's compliance engine tracks Swiss regulatory status alongside EU MDR, FDA QMSR, and market-specific requirements for suppliers operating across multiple geographies. For Swiss hospital tenders specifically:

• Tender monitoring across simap.ch and cantonal hospital procurement portals to capture Swiss public tender opportunities
• Regulatory certificate expiry tracking for CH-REP appointments, CE/MDR certificates, and ISO 13485 certification scope
• Tender compliance documentation assembly: swissdamed registration confirmation, CH-REP letter, and CE marking documentation packaged to Swiss procurement qualification requirements
• Integration with EU MDR and EUDAMED tracking so that Swiss and EU registration obligations are managed within a single compliance workflow

For teams monitoring Swiss tenders alongside EU and APAC opportunities, the combination of swissdamed compliance tracking and automated Swiss tender monitoring removes the manual monitoring burden across 26 cantonal procurement channels. Book a demo to see how Orbid AI handles Swiss market compliance, or explore our EUDAMED registration guide and EU MDR guide for the parallel European regulatory context.